{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:vm:propranolol-hemangioma",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:20:00.000Z",
    "updated": "2026-01-07T03:20:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.95,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/vascular-malformations",
    "type": "pharmacotherapy",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "Propranolol for Infantile Hemangioma",
    "description": "Beta-blocker therapy as first-line treatment for problematic infantile hemangiomas",
    "key_concepts": [
      {
        "concept": "Discovery",
        "details": "Serendipitous discovery in 2008 revolutionized infantile hemangioma management"
      },
      {
        "concept": "Mechanism",
        "details": "Vasoconstriction, decreased VEGF expression, apoptosis induction in endothelial cells"
      },
      {
        "concept": "Dosing",
        "details": "1-3 mg/kg/day in divided doses; continue through proliferative phase (typically 6-12 months)"
      },
      {
        "concept": "Monitoring",
        "details": "Monitor heart rate and blood pressure during initiation; watch for hypoglycemia"
      }
    ],
    "clinical_significance": "Propranolol is first-line treatment for problematic infantile hemangiomas"
  },
  "provenance": {
    "primary_sources": ["Léauté-Labrèze C et al. N Engl J Med 2015"]
  }
}
